PROFESSIONAL EDITION

The largest community of pharma leaders

PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of the Antiplatelet Effects of Ticagrelor

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)—- $PHAS #PhaseBio–PhaseBio Doses First Patients in Canada as part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

Source

Recent Articles